| A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection D Magirr, T Jaki, J Whitehead Biometrika 99 (2), 494-501, 2012 | 156 | 2012 |
| Some recommendations for multi-arm multi-stage trials J Wason, D Magirr, M Law, T Jaki Statistical methods in medical research 25 (2), 716-727, 2016 | 105 | 2016 |
| Modestly weighted logrank tests D Magirr, CF Burman Statistics in medicine 38 (20), 3782-3790, 2019 | 49 | 2019 |
| Sample size reassessment and hypothesis testing in adaptive survival trials D Magirr, T Jaki, F Koenig, M Posch PloS one 11 (2), e0146465, 2016 | 45 | 2016 |
| Flexible sequential designs for multi‐arm clinical trials D Magirr, N Stallard, T Jaki Statistics in Medicine 33 (19), 3269-3279, 2014 | 34 | 2014 |
| On model-based time trend adjustments in platform trials with non-concurrent controls MB Roig, P Krotka, CF Burman, E Glimm, SM Gold, K Hees, P Jacko, ... BMC medical research methodology 22 (1), 228, 2022 | 33 | 2022 |
| Simultaneous confidence intervals that are compatible with closed testing in adaptive designs D Magirr, T Jaki, M Posch, F Klinglmueller Biometrika 100 (4), 985-996, 2013 | 31 | 2013 |
| Considerations on covariates and endpoints in multi‐arm multi‐stage clinical trials selecting all promising treatments T Jaki, D Magirr Statistics in Medicine 32 (7), 1150-1163, 2013 | 30 | 2013 |
| The R package MAMS for designing multi-arm multi-stage clinical trials T Jaki, P Pallmann, D Magirr Journal of Statistical Software 88, 1-25, 2019 | 25 | 2019 |
| Non‐proportional hazards in immuno‐oncology: Is an old perspective needed? D Magirr Pharmaceutical Statistics 20 (3), 512-527, 2021 | 17 | 2021 |
| Influence of genetic background on bleeding phenotype in the tail‐tip bleeding model and recommendations for standardization: communication from the SSC of the ISTH A Schiviz, D Magirr, P Leidenmühler, M Schuster, EM Muchitsch, ... Journal of Thrombosis and Haemostasis 12 (11), 1940-1942, 2014 | 12 | 2014 |
| Adaptive survival trials D Magirr, T Jaki, F Koenig, M Posch arXiv preprint arXiv:1405.1569, 2014 | 12 | 2014 |
| Mams: Designing multi-arm multi-stage studies T Jaki, D Magirr, P Pallmann R package version, 2019 | 10 | 2019 |
| Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study S Brunner‐Ziegler, B Jilma, D Magirr, R Sunder‐Plassmann, GA Giurgea, ... British journal of haematology 167 (4), 547-553, 2014 | 9 | 2014 |
| Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism … A MacDonald, G Scarfe, D Magirr, T Sarvotham, J Charlton, W Brugger, ... Cancer chemotherapy and pharmacology 83, 787-795, 2019 | 8 | 2019 |
| Mams: Designing multi-arm multi-stage studies, 2014 T Jaki, D Magirr, P Pallmann URL http://CRAN. R-project. org/package= MAMS. R package version 0.3, 0 | 7 | |
| The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross … D Magirr, CF Burman Statistics in Biopharmaceutical Research 15 (2), 295-296, 2023 | 6 | 2023 |
| Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels M Żebrowska, M Posch, D Magirr Statistics in medicine 35 (12), 1972-1984, 2016 | 6 | 2016 |
| Subcommittee on Animal Models of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis (2014) Influence of genetic background … A Schiviz, D Magirr, P Leidenmühler, M Schuster, EM Muchitsch, ... J Thromb Haemost 12 (11), 1940-1942, 0 | 6 | |
| Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance D Magirr, JL Jiménez Clinical Trials 19 (2), 201-210, 2022 | 5 | 2022 |
